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Control of Blood Pressure After Stroke
Philip M.W. Bath, Nikola Sprigg
A cornerstone of primary stroke prevention is built ontreating “hypertension” in asymptomatic subjects whoare usually at low or medium vascular risk, dogma
based on the results of numerous randomized, controlled trials
and meta-analyses of them. Similarly, several trials have shown
that blood pressure (BP) should be lowered in patients who have
had a recent stroke.1–3 Note here the distinction between treating
hypertension in primary prevention and lowering BP in second-
ary prevention.
Three randomized trials were of sufficient size to help
determine clinical practice in patients with cerebrovascular
disease. The Post-stroke Antihypertensive Treatment Study
(PATS) found that treatment with the thiazide-like diuretic,
indapamide, reduced BP (by 5/2 mm Hg) and stroke recurrence
by 29% in 5665 Chinese patients.1 In contrast, the Heart
Outcomes Prevention Evaluation (HOPE) Study was a trial of
ramipril (angiotensin converting enzyme inhibitor [ACE-I]) in
9297 patients with high vascular risk in which 1013 patients had
a history of previous stroke. Within this subgroup, ramipril was
effective at reducing BP (by 11/4 mm Hg) whereas the compos-
ite outcome of stroke, myocardial infarction (MI), and vascular
death was reduced by 30%. The largest trial to date was the
Perindopril pROtection aGainst REcurrent Stroke Study
(PROGRESS), which assessed a treatment regime based on
another ACE-I, perindopril, given with or without indapamide
(at the investigators choice) in 6105 patients with previous
ischemic stroke or primary intracerebral hemorrhage.3 Overall,
active treatment was associated with a relative risk reduction
(RRR) in stroke of 28%; however, combined treatment
(perindoprilindapamide) was far more effective in reducing
both BP (12/5 mm Hg) and stroke (RRR 43%) than perindopril
alone (BP difference, 5/3 mm Hg; stroke RRR 5%, nonsignifi-
cant). Notably, treatment was particularly effective in patients of
Asian origin and in preventing recurrence in those whose index
event was a cerebral hemorrhage (rather than infarct).3
A meta-analysis of these trials and 4 earlier smaller ones
reported that antihypertensive therapy was effective in reducing
recurrent stroke (odds ratio [OR], 0.76), MI (OR, 0.79), and
vascular events (OR, 0.79).4 Heterogeneity between drug classes
was apparent: -receptor antagonists did not seem to reduce any
vascular events, diuretics alone reduced stroke but not MI, and
ACE-I reduced MI but not stroke. However, the most effective
intervention was dual therapy, which reduced each of the 3
outcomes (Figure 1).4 More recently, the relatively small Mor-
bidity and Mortality After Stroke–Eprosartan Versus Nitrendip-
ine for Secondary Prevention (MOSES) Trial reported that
eprosartan (angiotensin receptor antagonist) was more effective
than nitrendipine (calcium channel blocker [CCB]) in preventing
stroke recurrence,5 a result that is difficult to interpret, because
the effectiveness of CCBs in patients with previous stroke is
unknown. A much larger trial, Prevention Regimen For Effec-
tively avoiding Second Stroke (PRoFESS, n20 000) is under-
way, which is assessing the effect of telmisartan (angiotensin
receptor antagonist) on stroke recurrence in patients with ische-
mic stroke.
These data strongly support the routine use of antihyperten-
sive agents in patients with previous ischemic stroke. And yet,
the article published in this edition of the journal from the North
East MElbourne Stroke Incidence Study (NEMESIS) by Paul
and Thrift6 is depressing, suggesting that many patients out in
the community are hypertensive some 5 years after their event
and, indeed, 5 years after the publication of PROGRESS. Paul
and Thrift6 found that 82% of their patients had hypertension
that was uncontrolled (BP 140/90 mm Hg) in more than one
third of patients. Although most were receiving some antihyper-
tensive medication, a small group (6%) of patients were unaware
that their BP was elevated suggesting, perhaps, that they were
not receiving active primary care follow-up. It is well known that
many patients out of the environment of trials cease to take
long-term medication; for example, 30% of those with essen-
tial hypertension have ceased therapy by 12 months7; hence, it is
vital that patients with previous stroke have long-term follow-up
in the community to motivate compliance. Perhaps unsurpris-
ingly, persistence with therapy seems to be higher with newer
agents (such as ACE-I).7
It is increasingly clear that most patients need 2 drugs to
control their BP, as seen in trials such as HOPE and
PROGRESS.2,3 NEMESIS found that most patients (65%) were
on monotherapy,6 which will explain, in part, the lack of BP
control. Interestingly, the most common drug class for mono-
therapy was ACE-I, perhaps reflecting that both PROGRESS
and NEMESIS arose from Australia, although this observation is
also in keeping with a recent US study demonstrating a large
increase in use of ACE-I.8 Dual therapy may also be inadequate
for controlling BP, especially if inappropriate drug combinations
are used. For example, combining an ACE-I and -receptor
antagonist (2 classes that suppress the renin system), as was done
in 4% of NEMESIS patients, is unlikely to lead to synergistic
effects, especially in older people9 who tend to have low renin
levels anyway. This combination was associated with uncon-
trolled hypertension. Another inappropriate combination is use
of a CCB and diuretic. In contrast, the most common dual
therapy combination associated with adequate BP control in
NEMESIS involved an ACE-I and diuretic,6 drugs that have
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opposing effects on the renin system. The use of optimal com-
binations of antihypertensive agents is now recommended in
national guidelines.10 In addition to lack of awareness and poor
compliance, therapeutic inertia (the failure of health care pro-
viders to increase treatment when therapy goals are unmet)
accounts for a large proportion of uncontrolled hypertension.7,11
BP control is lowest in those patients whose providers have high
inertia, whereas patients of providers with low inertia have an
increased number of medications and better control.
Elevated BP is a potent modifiable risk factor for stroke,
whereas many patients who have has a previous stroke are
hypertensive afterward. Lowering BP is an effective method
for reducing the risk of subsequent stroke and it is beholden
on all of those who look after stroke patients, whether general
practitioners, stroke physicians, or neurologists, to ensure that BP
control is achieved. Most patients will need2 drugs, and combi-
nations should be logical and based on class pharmacological
activities, especially taking account of effects on the renin system.
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Forrest plot of the effects of antihypertensive
therapy in patients with previous stroke or
transient ischemic attack on subsequent
stroke (fatal and nonfatal). Reprinted with
permission from Reference 4.
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